First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V.

MONTREAL , Feb. 13, 2025 /PRNewswire/ - Lightspeed Commerce Inc. (NYSE: LSPD) (TSX: LSPD) ("Lightspeed" or the "Company"), today released the registration and attendance information for its Capital Markets Day at the New York Stock Exchange on Wednesday, March 26, 2025. Lightspeed is the unified POS and payments platform for ambitious entrepreneurs to accelerate growth, provide the best customer experiences and become a go-to destination in their space.

DALLAS and TYSONS, Va., Feb. 13, 2025 (GLOBE NEWSWIRE) -- The Dallas Wings and TEGNA's (NYSE: TGNA) KFAA in Dallas have announced a landmark broadcast rights agreement, making the station the exclusive local television partner of the Dallas Wings.

Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinical trials Despite the increased time required to obtain informed consent, 100% of those surveyed continue to offer patients these innovative investigational treatment options CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented novel research evaluating the patient experience and barriers to enrollment and participation in cell and gene therapy (CGT) trials.

TEL AVIV, Israel , Feb. 13, 2025 /PRNewswire/ -- Arbe Robotics Ltd. (Nasdaq: ARBE) (TASE: ARBE), a global leader in perception radar solutions, today announced that management will be participating in the following investor conferences in February: Oppenheimer 10th Annual Emerging Growth Conference Format: Virtual meetings When: Tuesday, February 25 Canaccord Sustainability Summit Format: Virtual panel and meetings When: Wednesday, February 26 Investors who wish to schedule one-on-one virtual meeting with Arbe's management during the conferences may refer to their bank contact person or to [email protected].

The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse events following troculeucel therapy. Troculeucel therapy was well-tolerated and resulted in beneficial effects on protein aggregate levels and neuroinflammatory biomarkers in the cerebrospinal fluid, with decreases in pTau181 and GFAP appearing to be dose dependent.

Management to Host Second Quarter Fiscal 2025 Earnings Conference Call to Discuss Transaction at 5:00 p.m. ET Today ORLANDO, Fla.

BOSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2025 to report its fourth quarter and full year 2024 financial results and provide a corporate update.

LONGMONT, Colo. , Feb. 13, 2025 /PRNewswire/ -- S&W Seed Company (Nasdaq: SANW), or S&W, today announced financial results for the three months ended December 31, 2024.

NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Magnite (Nasdaq: MGNI), the largest independent sell-side advertising company, today announced that members of its executive team will host in-person investor meetings at the Susquehanna Financial Group 14th Annual Technology Conference in New York City on Thursday, February 27, 2025. About Magnite We're Magnite (NASDAQ: MGNI), the world's largest independent sell-side advertising company.

Based on FAA Part 107 commercial drone registration data from 2021 to the present day marks a significant accomplishment for AgEagle in the commercial UAS industry WICHITA, Kan., Feb. 13, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE: UAVS) a leading provider of best-in-class unmanned aerial systems (UAS), sensors and software solutions for customers worldwide in the commercial and government verticals, announces that based on its internal review of FAA Part 107 commercial drone registration data from 2021 to present day indicates the Company's eBee UAS was the most used conventional fixed wing drone for U.S. commercial operators.

WARREN, N.J. , Feb. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2024 financial results and provide an update on the company's business and outlook on Thursday, Feb. 27, at 4:30 p.m.

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of Calendar 2025 Secured Private Placement Financing of $15 Million in Upfront Gross Proceeds with the Potential to Receive up to an Additional $15 Million in Potential Warrant Exercise Proceeds for an Aggregate of Up to Approximately $30 Million in Potential Total Gross Proceeds PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, …

"Our focus in 2024 was stabilizing the business and implementing fundamental changes to transform our company," said Gil West, Hertz CEO. "With our new leadership team and organizational structure in place, we are well positioned to execute our strategy with rigor and at pace.

HAMILTON, Bermuda , Feb. 13, 2025 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore", the "Company" or "we") today announced results for the three and twelve months ended December 31, 2024. Highlights and Recent Activity Reported Adjusted earnings of $10.3 million for the three months ended December 31, 2024, or $0.25 Adjusted earnings per basic share and diluted share, compared to Adjusted earnings of $26.1 million, or $0.63 Adjusted earnings per basic share and diluted share for the three months ended December 31, 2023.

1% Growth in Total Revenues to $1.3 billion for the Fourth Quarter of 2024 1% Growth in Total Revenues to $5.1 billion for Fiscal Year 2024 Delivered record WSE retention in 2024 DUBLIN, Calif. , Feb. 13, 2025 /PRNewswire/ -- TriNet Group, Inc. (NYSE: TNET), a leading provider of comprehensive and flexible human capital management (HCM) solutions for small and medium-size businesses (SMBs), today announced financial results for the fourth quarter and full year ended December 31, 2024.

GameSquare's world-building campaigns drove over 125 million minutes of gameplay and generated $3.9 million in revenue in 2024 Excellent results in 2024 support a strong pipeline and management expects revenue from world-building projects to increase 100% in 2025 FRISCO, TX / ACCESS Newswire / February 13, 2025 / GameSquare Holdings, Inc. (NASDAQ:GAME), ("GameSquare", or the "Company"), a next-generation media company with roots in gaming and creator entertainment, today announced record annual sales for 2024 from its expanding world-building solutions. During 2024, GameSquare created unique and innovative experiences for leading brands including recent deployments for Paramount's SpongeBob SquarePants, Top Golf, 5-Hour …

BURLESON, TEXAS / ACCESS Newswire / February 13, 2025 / Sadot Group Inc. (Nasdaq:SDOT) ("Sadot Group" or the "Company") today announced the appointment of Ms. Catia Jorge as its new Chief Executive Officer, effective immediately.

Unilever PLC (NYSE:UL ) Q4 2024 Earnings Conference Call February 13, 2025 3:00 AM ET Company Participants Hein Schumacher - CEO Fernando Fernandez - CFO Jemma Spalton - Head of IR Conference Call Participants Warren Ackerman - Barclays Celine Pannuti - JPMorgan Chase & Co. Jeffrey Stent - BNP Paribas Exane Jean-Olivier Nicolai - Goldman Sachs Group Guillaume Delmas - UBS Jeremy Fialko - HSBC Victor Ma - TD Securities Thomas Sykes - Deutsche Bank Hein Schumacher Good morning and welcome to Unilever's Full Year Results. Thank you for joining us.